Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjƶgren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: tramadol

FDA Receives Upadacitinib Application for Ankylosing Spondylitis & Approves Tramadol Hydrochloride Oral Solution

Michele B. Kaufman, PharmD, BCGP  |  September 30, 2020

In August, Abbvie submitted a new drug application for upadacitinib to treat ankylosing spondylitis. And in September, the FDA approved an oral solution of tramadol hydrochloride for pain.

Filed under:Axial SpondyloarthritisDrug Updates Tagged with:Ankylosing SpondylitisAS Resource CenterFDAPainPain Managementtramadol hydrochlorideU.S. Food and Drug Administration (FDA)upadacitinib

IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval

Michele B. Kaufman, PharmD, BCGP  |  July 2, 2018

In its first phase 3 clinical trial, intravenous tramadol has met its primary endpoint for relieving postoperative pain…

Filed under:AnalgesicsDrug Updates Tagged with:FDAFDA approvalmeloxicamnonsteroidal antiinflammatory drug (NSAID)Painpost-surgerytramadolU.S. Food and Drug Administration (FDA)

FDA Warns ‘Don’t Use Tramadol in Children’ & More

Michele B. Kaufman, PharmD, BCGP  |  October 21, 2015

New studies show ABT-494 is an effective alternative to anti-TNF alpha agents, as well as methotrexate, for RA. Also, the FDA issued a warning against using tramadol for young patients due to their increased risk of respiratory side effects…

Filed under:Drug Updates

What Every Clinician Should Know about Ramadan & Intermittent Fasting

Mohammad A. Ursani, MD, FACP, RhMSUS, Iman Qaiser, MD, & Mamdouh Mahmoud, PhD  |  February 7, 2024

Intermittent fasting—defined as alternating between cycles of eating and going without food over a given period of time—has become popular with individuals seeking to lose weight or balance their lifestyle in recent years. During Ramadan (a period based on the Gregorian calendar that changes from year to year), able-bodied Muslims are obligated to observe a…

Filed under:OpinionPatient Perspective Tagged with:adherencefastingintermittent fasting

Small Fiber Neuropathy for the Rheumatologist

Michael Cammarata, MD  |  January 10, 2024

Small fiber neuropathy is a common form of peripheral neuropathy with multiple potential etiologies and a varied clinical presentation. It can’t be detected by nerve conduction studies, making it an elusive and often overlooked entity. Small fiber neuropathy is well documented in several rheumatic diseases, and its symptom burden can profoundly affect quality of life….

Filed under:ConditionsOther Rheumatic ConditionsSjƶgren’s DiseaseSystemic Lupus ErythematosusSystemic Sclerosis Tagged with:neuropathyPeripheral Neuropathysmall fiber neuropathy

The ACR Knowledge Bowl Playbook

Guy Katz, MD, Joanna Marco, MD, & Jean Liew, MD, MS  |  June 26, 2023

One of the most fun events at every annual meeting is the ACR Knowledge Bowl. In this quiz show-style trivia game, fellows form teams to compete for top prizes. There’s a charismatic host, a panel of esteemed judges and an auditorium packed with cheering spectators. Beyond the fun of competing against your peers from other…

Filed under:From the CollegeHome SliderProfessional Topics Tagged with:ACR Convergence 2023ACR Knowledge Bowl

3 AC&R Study Summaries: MoCA Screening in SLE, Pediatric Social Disadvantages & Surgical Weight Loss Interventions

Oshrat E. Tayer-Shifman, MD; Kimberley Yuen, BSc, MD; Zahi Touma, MD, PhD, FACP, FACR; William Daniel Soulsby, MD; Aleksandra Kostic, BSE; Valia Leifer, MA; & Elena Losina, PhD, MSC  |  November 9, 2022

MoCA as a Screening Test in SLE Assessing the utility of the Montreal Cognitive Assessment (MoCA) By Oshrat E. Tayer-Shifman, MD, Kimberley Yuen, BSc, MD, & Zahi Touma, MD, PhD, FACP, FACR Why was this study done? Cognitive impairment is a common manifestation of systemic lupus erythematosus (SLE), with a prevalence of 40% based on…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Arthritis Care & ResearchDisparitiesObesityOsteoarthritisReading Rheum

A Case of Nodular Rash & Painful Joints

Vania Lin, MD, MPH, Rebecca Johnson, MD, & Lisa Suter, MD  |  October 10, 2022

Polyarteritis nodosa (PAN) is a necrotizing vasculitis, predominantly involving medium-sized arteries, that causes systemic disease, and, less commonly, cutaneous-limited disease. The population prevalence for PAN ranges from 2 to 33 per million.1-3 Estimates vary due to the increased recognition and classification of other forms of vasculitides over time and variation in the regional prevalence of…

Filed under:ConditionsVasculitis Tagged with:case reportFellowsFellows Forumpolyarteritis nodosa

FDA Approves First Interchangeable Biosimilar to Adalimumab, Plus a Combination Drug Approved

Michele B. Kaufman, PharmD, BCGP  |  November 17, 2021

Cyltezo (adalimumab-adbm) may be interchanged for Humira (adalimumab) for all indications, according to an October decison by the FDA. The FDA has also approved a new combination of celecoxib and tramadol for pain management.

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:adalimumabadalimumab-adbmBiosimilarscelecoxib (Elyxyb)interchangeabilityPain Managementtramadol

High Opioid Prescription Rates Seen in Emergency Department-Treated Gout

Kurt Ullman  |  November 2, 2020

Acute gout can be very painful, causing patients to seek treatment in the emergency department. A retrospective study of pain interventions for gout in RhodeĀ  Island found that nearly 30% of patients received prescriptions for opioid medications over 30 months. Of these prescriptions, over 80% were for patients who had never been exposed to opioids…

Filed under:AnalgesicsConditionsGout and Crystalline Arthritis Tagged with:Goutopioid crisis

  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences